3. Results
heart failure, Orthopnea, cardiac death, dyspnea
EVENTS, HEART FAILURE, CARDIAC DEATH, EVENT
Four hundred seventy-six eligible patients who visited our cardiovascular clinic were selected initially. Thirty-nine patients were excluded according to the mentioned exclusion criteria. Two patients changed from ticagrelor to clopidogrel due to the onset of dyspnea. No patients were hospitalized due to dyspnea. The remaining 437 patients (154 women and 283 men) were included in this study, 233 were allocated to the “clopidogrel group” and 214 to the “ticagrelor group” (The mean age of the patients was 62 ± 9 years. The groups' baseline characteristics are compared in In the ticagrelor group, 95 patients (44.8%) reported dyspnea at rest, compared with 44 patients (19.7%) in the clopidogrel group (OR = 3.3, 95% CI = 2.50–5.06, and Orthopnea was experienced by 22 patients (10.2%) in the ticagrelor group and 13 patients (5.8%) in the clopidogrel group (OR = 1.81, 95% CI = 0.89–3.7, and A higher percentage of patients in the clopidogrel group (91.9%) adhered completely to their medication compared to the ticagrelor group (87.8%). However, this difference was not statistically significant (A MACE was seen in six patients of the ticagrelor group (2.8%), all presenting with ACS. On the other hand, there were 16 events (7.6%) in the clopidogrel group, consisting of 14 cases of ACS (6.2%), one heart failure (0.4%), one cerebrovascular event (0.4%), and one cardiac death (0.4%). The difference was statistically significant (OR = 2.86, 95% CI = 1.1–7.4, and 